SCHEMBL26205855

SCHEMBL26205855

Cc1ccc(N2C(=O)C=C(Nc3cc(F)c(C)c(F)c3)C2=O)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ MGLL Q99685 2/20 0.39
▸ ALDH1A1 P00352 5/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ F2 P00734 1/20 0.38
▸ ELANE P08246 1/20 0.38
▸ CTSG P08311 1/20 0.38
▸ CMA1 P23946 1/20 0.38
▸ CTRC Q99895 1/20 0.38
▸ POLB P06746 2/20 0.36
▸ HPGD P15428 1/20 0.36
▸ NPC1 O15118 2/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ TSHR P16473 1/20 0.35
▸ CASP1 P29466 1/20 0.35
▸ CASP7 P55210 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ MAPT P10636 2/20 0.33
▸ TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26205834 0.93 KMT2A (0.54) MEN1KMT2AMGLLALDH1A1KDM4E
SCHEMBL24430074 0.90 MEN1 (0.50) MEN1KMT2AMGLLALDH1A1KDM4E
SCHEMBL26205886 0.90 KMT2A (0.50) MEN1KMT2AMGLLALDH1A1KDM4E
SCHEMBL26205843 0.90 MEN1 (0.68) MEN1KMT2AMGLLALDH1A1KDM4E
SCHEMBL26205804 0.89 MEN1 (0.49) MEN1KMT2AMGLLALDH1A1KDM4E
SCHEMBL26205890 0.87 MEN1 (0.48) MEN1KMT2AALDH1A1KDM4ENPC1
SCHEMBL26205848 0.87 ALDH1A1 (0.54) MEN1KMT2AMGLLALDH1A1KDM4E
SCHEMBL26205868 0.87 MEN1 (0.48) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL26205857 0.87 MEN1 (0.51) MEN1KMT2AMGLLALDH1A1KDM4E
SCHEMBL26205908 0.87 MEN1 (0.48) MEN1KMT2AMGLLALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11753374-B2 Compounds for the treatment of acute and chronic kidney disease Southern Reserach Institute (US) 2023-09-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11753374-B2 Compounds for the treatment of acute and chronic kidney disease HMOX1, GLS, HMOX2 MEN1 4171/4885KMT2A 2088/4885MGLL 1168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback